BioCentury
ARTICLE | Company News

MirImmune, RXi Pharmaceuticals deal

October 17, 2016 7:00 AM UTC

RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a 19.99% stake in RXi and would be eligible for undisclosed milestones. The stake is valued at about $2.2 million based on RXi’s close at $1.69 on Oct. 11, the day before the deal was announced, and 6.6 million shares outstanding on Aug. 5. RXi may exercise the option before April 5, 2017. ...